Merck & Co., Inc: Prostatic Neoplasms trials
The registry lists 22 Prostatic Neoplasms studies with Merck & Co., Inc as lead sponsor. 4 are open to participants now and 6 have results posted.
Phase 1 11Phase 2 7Phase 3 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Not yet recruitingNCT07908524Phase 1/2
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)RecruitingNCT06925737Phase 3
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)RecruitingNCT06136650Phase 3
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)RecruitingNCT06136624Phase 3
- Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China ExtensionTerminatedNCT04907227Phase 3Results posted
- Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)CompletedNCT03834519Phase 3Results posted
- Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)CompletedNCT03834506Phase 3Results posted
- Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)TerminatedNCT03834493Phase 3Results posted
- Study of HPN424 in Patients With Advanced Prostate CancerTerminatedNCT03577028Phase 1/2Results posted
- A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)CompletedNCT00753415Phase 1Results posted
- A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)CompletedNCT06566989Phase 1
- A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)CompletedNCT06554639Phase 1
- A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)CompletedNCT06136598Phase 1
- A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)CompletedNCT06104449Phase 1
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruitingNCT04471727Phase 1/2
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruitingNCT02861573Phase 1/2
- Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)CompletedNCT00777959Phase 2
- A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)WithdrawnNCT00691899Phase 3
- A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)TerminatedNCT00539968Phase 1/2
- MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)CompletedNCT00302471Phase 1
- Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)CompletedNCT00110188Phase 2
- Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)CompletedNCT00060476Phase 3